VDA-1102 Ointment

VDA-1102 ointment is being developed under an IND from the FDA as a topical treatment for a variety of skin cancers. It has completed a randomized, double-blinded, placebo-controlled, dose-escalation Phase 1 study in healthy older-adult volunteers which revealed no safety concerns.

VDA-1102 AK

A Phase 2 B was successfully completed in 2019 (NCT 03538951) demonstrating a 40% Complete Clearance and 80% lesions reduction in 50% of the population with a good skin permeability to the present formulation. A Phase 2C with a slightly enhanced skin permeability is programmed to late 2023 or early 2024.

VDA-1102 CTCL

In view of the exceptional safety found in the Phase 2B for AK, the Company was allowed to enter directly into a Phase 2 for CTCL. The Phase 2 was initiated in December 2020 under Ministry of Health of Israel at Beilinson Hospital and is to continue through 2023-2024.